tetano
Editor, Senior Moderator
J Thromb Thrombolysis
. 2024 Nov 15.
doi: 10.1007/s11239-024-03057-z. Online ahead of print. Impact of antiplatelets, anticoagulants and cyclic nucleotide stimulators on neutrophil extracellular traps (NETs) and inflammatory markers during COVID-19
José D Oliveira[SUP] 1 2 [/SUP], Gislaine Vieira-Damiani[SUP] 3 [/SUP], Letícia Q da Silva[SUP] 1 4 [/SUP], Guilherme R Leonardi[SUP] 5 [/SUP], Camila O Vaz[SUP] 1 2 [/SUP], Bruna C Jacintho-Robison[SUP] 1 2 [/SUP], Bruna M Mazetto[SUP] 1 4 [/SUP], Erich V de Paula[SUP] 1 4 [/SUP], Fabíola Z Monica[SUP] 5 [/SUP], Fernanda A Orsi[SUP] 6 7 8 [/SUP]
Affiliations
While the association between coronavirus disease-19 (COVID-19) and neutrophils extracellular traps (NETs) is recognized, uncertainties remain regarding its precise onset, timing of resolution and target therapy. To assess changes in inflammatory and NET markers during the first week of COVID-19 hospitalization, and the association with disease severity. "In vitro" experiments investigated the effect of antiplatelets, anticoagulants, and cyclic nucleotide stimulators on NETs release. Prospective cohort study, changes in interleukin (IL)-6, IL-8, IL-17, TNF-α, RANTES, PF4, and citrullinated-H3 (citH3) levels within each outcome group was evaluated using ANOVA. Differences between moderately ill, critically ill, and non-survivors were determined using Kruskal-Wallis and logistic regression. Healthy neutrophils were stimulated with phorbol-12-myristate-13-acetate (PMA) or COVID-19 sera and treated with unfractionated heparin (UFH), low molecular weight heparin (LMWH), aspirin (ASA), ticagrelor, cinaciguat, sildenafil, and milrinone. The proportion of NETosis was assessed using IncuCyte Cell Imager. Of the 125 patients, 40.8% had moderate COVID-19, 40.8% had critical COVID-19 but recovered, and 18.4% died. From admission to hospitalization day 8, IL-6 levels decreased in moderately and critically ill, but not in non-survivors, while citH3 levels increased in critically ill and non-survivors. IL-6, IL-8, and TNF-α levels were associated with critical and fatal COVID-19. The release of NETs by neutrophils stimulated with PMA or COVID-19 sera was decreased in the presence of ASA, UFH, LMWH and cyclic nucleotide stimulators in a dose-dependent manner. In the first week of hospitalization, NET markers rose later than inflammatory markers in severe COVID-19 cases. Cyclic nucleotide stimulators, ASA and heparin may emerge as treatment approaches as they may modulate NETosis.
Keywords: Anticoagulants; Antiplatelet agents; COVID-19; Cyclic nucleotides; Neutrophil extracellular traps.
. 2024 Nov 15.
doi: 10.1007/s11239-024-03057-z. Online ahead of print. Impact of antiplatelets, anticoagulants and cyclic nucleotide stimulators on neutrophil extracellular traps (NETs) and inflammatory markers during COVID-19
José D Oliveira[SUP] 1 2 [/SUP], Gislaine Vieira-Damiani[SUP] 3 [/SUP], Letícia Q da Silva[SUP] 1 4 [/SUP], Guilherme R Leonardi[SUP] 5 [/SUP], Camila O Vaz[SUP] 1 2 [/SUP], Bruna C Jacintho-Robison[SUP] 1 2 [/SUP], Bruna M Mazetto[SUP] 1 4 [/SUP], Erich V de Paula[SUP] 1 4 [/SUP], Fabíola Z Monica[SUP] 5 [/SUP], Fernanda A Orsi[SUP] 6 7 8 [/SUP]
Affiliations
- PMID: 39546241
- DOI: 10.1007/s11239-024-03057-z
While the association between coronavirus disease-19 (COVID-19) and neutrophils extracellular traps (NETs) is recognized, uncertainties remain regarding its precise onset, timing of resolution and target therapy. To assess changes in inflammatory and NET markers during the first week of COVID-19 hospitalization, and the association with disease severity. "In vitro" experiments investigated the effect of antiplatelets, anticoagulants, and cyclic nucleotide stimulators on NETs release. Prospective cohort study, changes in interleukin (IL)-6, IL-8, IL-17, TNF-α, RANTES, PF4, and citrullinated-H3 (citH3) levels within each outcome group was evaluated using ANOVA. Differences between moderately ill, critically ill, and non-survivors were determined using Kruskal-Wallis and logistic regression. Healthy neutrophils were stimulated with phorbol-12-myristate-13-acetate (PMA) or COVID-19 sera and treated with unfractionated heparin (UFH), low molecular weight heparin (LMWH), aspirin (ASA), ticagrelor, cinaciguat, sildenafil, and milrinone. The proportion of NETosis was assessed using IncuCyte Cell Imager. Of the 125 patients, 40.8% had moderate COVID-19, 40.8% had critical COVID-19 but recovered, and 18.4% died. From admission to hospitalization day 8, IL-6 levels decreased in moderately and critically ill, but not in non-survivors, while citH3 levels increased in critically ill and non-survivors. IL-6, IL-8, and TNF-α levels were associated with critical and fatal COVID-19. The release of NETs by neutrophils stimulated with PMA or COVID-19 sera was decreased in the presence of ASA, UFH, LMWH and cyclic nucleotide stimulators in a dose-dependent manner. In the first week of hospitalization, NET markers rose later than inflammatory markers in severe COVID-19 cases. Cyclic nucleotide stimulators, ASA and heparin may emerge as treatment approaches as they may modulate NETosis.
Keywords: Anticoagulants; Antiplatelet agents; COVID-19; Cyclic nucleotides; Neutrophil extracellular traps.